Boston Trust Walden Corp Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 1st, 2023

Boston Trust Walden Corp raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 982,387 shares of the company’s stock after buying an additional 74,831 shares during the quarter. Johnson & Johnson accounts for about 1.5% of Boston Trust Walden Corp’s holdings, making the stock its 4th biggest position. Boston Trust Walden Corp’s holdings in Johnson & Johnson were worth $173,539,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares during the last quarter. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after buying an additional 2,815,655 shares during the period. GQG Partners LLC raised its holdings in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of Johnson & Johnson by 52.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after purchasing an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Johnson & Johnson by 37.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after purchasing an additional 1,805,632 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on JNJ shares. Citigroup lifted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. SVB Leerink lowered their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Piper Sandler lowered their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Guggenheim assumed coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $173.67.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $155.00 on Friday. The business has a 50 day moving average of $158.02 and a 200-day moving average of $167.12. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The company has a market capitalization of $403.66 billion, a P/E ratio of 23.00, a P/E/G ratio of 2.64 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.13 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 67.06%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.